Aktienanalyse zu Clearpoint Neuro Inc (CLPT)CLPTClearpoint Neuro Inc

ClearPoint Neuro, Inc. is a commercial-stage medical device company that develops and commercializes integrated systems used in minimally invasive neurosurgical procedures in the brain. The Company provides clinical products and preclinical development services for controlled drug and device delivery. Its business consists of two components: a business providing medical devices for neurosurgical applications, and a business focused on partnerships in the biologics and drug delivery space. Its primary medical device product, the ClearPoint system, is an integrated system comprised of hardware components, disposable components, and intuitive, menu-driven software. The primary applications for the ClearPoint system are to target and guide the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, and the infusion of pharmaceuticals into the brain. It provides consulting services to its pharmaceutical and other medical technology partners. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

ClearPoint Neuro Inc (CLPT) is currently a hold. The stock is priced at $15.55, which is below the analyst price targets ranging from $22 to $30. However, the company is facing significant operational challenges, with a net income loss of $11.3 million in Q2 2026 and a forward P/E ratio of 12.11, indicating potential undervaluation but also underlying financial stress.